Thompson, Alastair M <br/><br/>
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.  [electronic resource] 

 -  Breast cancer research and treatment  Jan 2011 
 - 279-87 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-010-1139-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Cytochrome P-450 CYP2D6--genetics<br/>Cytochrome P-450 CYP2D6 Inhibitors<br/>Disease-Free Survival<br/>Drug Interactions<br/>Enzyme Inhibitors--therapeutic use<br/>Estrogen Receptor Modulators--metabolism<br/>Female<br/>Gene Frequency<br/>Genotype<br/>Humans<br/>Kaplan-Meier Estimate<br/>Medication Adherence<br/>Middle Aged<br/>Phenotype<br/>Proportional Hazards Models<br/>Risk Assessment<br/>Risk Factors<br/>Tamoxifen--metabolism<br/>Time Factors<br/>Treatment Outcome